Phase I Trial of CART123 Cells Given in Combination With Ruxolitinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Latest Information Update: 16 Jan 2025
Price :
$35 *
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 16 Jan 2025 New trial record